Minireviews
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1478-1489
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1478
Table 1 Summary of published studies of stereotactic body radiotherapy in intrahepatic cholangiocarcinoma
Ref.CountryDesignPatient characteristics (reason for inoperability)Total patientsNo. iCCA (%)Median follow-up/months (range)Outcomes (1 yr)1
Major side effects (CTC > 3)
Local control (%)
Progression free survival (%)
Overall survival (%)
Shen et al[46], 2017ChinaRetrospectiveUnresectable: (1) 7/28 Medical; (2) 16/28 Technical; and (3) 5/28 Advanced age2828 (100)16 (3-42)89.350.057.10
Liu et al[47], 2017TaiwanRetrospectiveUnresectable: (1) Medical 3/15; and (2) Surgical 12/151512 (80)29.048.5-50.30
Thuehøj et al[48], 2022DenmarkRetrospectiveUnresectable, locally advanced4115 (37)9.5 (0-66.5)85.431.748.8-
Tao et al[49], 2016United StatesRetrospectiveUnresectable, locally advanced7979 (100)24 (4-33)81.091.087.00
Tse et al[51], 2008CanadaProspective, phase IUnresectable, locally advanced (includes HCC)4110 (24)17.6 (range 10.8-39.2)65.0 (all patients)-58.00
Mahadevan et al[52], 2015United StatesRetrospectiveUnresectable: (1) Medical 3/34; and (2) Surgical 29/34. R1 Resection: 2/343431 (91)38 (8-71)88.0-58.00
Barney et al[53], 2012United StatesRetrospectiveUnresectable: 6/12 lesions. Recurrent: 6/12 lesions106 (60)14 (2-26)100%-KM 73.0%0
Brunner et al[54], 2019Germany and SwitzerlandRetrospective, multicentreUnresectable, unclear reasons6441/82 lesions (50%)35 (7-91) for survivors89-810
Weiner et al[55], 2016United StatesProspective, phase IUnresectable, locally advanced (includes HCC)2614 (54) including 2 biphenotypic ICCA and HCC8.8 (0.3-33)91 (all patients)6851Grade IV lymphopenia-1 patient; Grade V hepatic failure-2 patients
Kozak et al[56], 2020United StatesRetrospectiveUnresectable disease4026 (63)18 (1-100)70 (all patients)-66 (all patients)0
Sebastian et al[59], 2019United StatesRetrospective, population database study, comparative study between SABR, TARE and CRTUnresected, locally advanced disease27-SABR; 52-CRT; TARE-60141 (100%)17--Propensity matched hazard ratio of overall survival for SABR vs CRT-0.22; vs TARE 0.58Not reported
Jung et al[60], 2014South KoreaRetrospectiveUnresectable and recurrent disease after surgery28-Unresectable; 30-Recurrent33 (57)10 (1-97)Unresectable-76; Recurrent-91Overall-26Unresectable-29; Recurrent-532-Cholangitis; 1-Gastric perforation
Franzese et al[61], 2020ItalyRetrospective49/51 (96%) Recurrent metastatic disease after surgical resection51 (includes GB adenoCa)34 (66)-iCCA and eCCA grouped together 14 (3-95)74.732.863.20
Ibarra et al[62], 2012United StatesRetrospectiveUnresectable disease21-HCC; 11-iCCA11 (34)7.8 (1.4-17.9)55.5-450